Prosecution Insights
Last updated: April 18, 2026
Application No. 18/254,668

PESTICIDAL COMPOSITIONS

Non-Final OA §112
Filed
May 26, 2023
Examiner
IVANOVA, SVETLANA M
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Syngenta Crop Protection AG
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
2y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allow Rate
417 granted / 828 resolved
-9.6% vs TC avg
Strong +51% interview lift
Without
With
+51.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
32 currently pending
Career history
860
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
41.9%
+1.9% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 828 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 10, 14 and 15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 10 is directed to: “The aqueous composition according to claim 9, wherein the adjuvant is selected from a mineral oil, a vegetable oil, an esterified vegetable oil, a methylated vegetable oil or an alkyl ester phosphate-based adjuvant, and preferably, an alkyl ester phosphate-based adjuvant.” A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 10 recites the broad recitation “wherein the adjuvant is selected from a mineral oil, a vegetable oil, an esterified vegetable oil, a methylated vegetable oil or an alkyl ester phosphate-based adjuvant”, and the claim also recites “, and preferably, an alkyl ester phosphate-based adjuvant.” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claims 14 and 15 recite the limitation "The method according to claim 10" in line 10. There is insufficient antecedent basis for this limitation in the claims, as claim 10 is a composition, not a method claim. Claim 10 further does not recite any plant, whereas claims 14 and 15 further lack antecedent basis for the recited “the plant”. Allowable Subject Matter Claims 1-9 and 11-13 are allowable. The following is an Examiner’s statement pertaining to the indication of allowable subject matter. Applicant performed studies, and was able to demonstrate considerably better chemical stability in a Composition B according to Applicant’s claims with active ingredients spiropidion and acetamiprid and with the further presence of the organic acid citric acid, as compared to a Composition A lacking citric acid. See Tables 1 and 2. PNG media_image1.png 388 744 media_image1.png Greyscale PNG media_image2.png 384 757 media_image2.png Greyscale The closest prior art are the following references: -WO 2013/107793 A2 to Buchholz et al. (“Buchholz”) Buchholz relates to mixtures of pesticidally active ingredients and to methods of using the mixtures to control insects, acarines, nematodes or molluscs. The mixtures comprise component A, selected from a compound of formula (I) PNG media_image3.png 505 709 media_image3.png Greyscale , and component B, which is selected from acetamiprid. Unlike Applicant’s claims, the mixtures do not comprise organic acids. - WO 2023017120 A1 to Gortz et al. (“Gortz”) Gortz relates to active compound combinations comprising as compound (A) methyl 2-[2- chloro-4-(4-chlorophenoxy)phenyl]-2-hydroxy-3-(l,2,4-triazol-l-yl)propanoate, 2-[2-chloro-4-(4-chloro- phenoxy)phenyl]-2-hydroxy-3-(l,2,4-triazol-l-yl)propanoic acid or a mixture thereof, as compound (B) a further specified fungicide and optionally as compound(s) (C) one or more further fimgicide(s). Moreover, the invention relates to fungicide compositions comprising such compound combination and to the use of the compound combinations and the fungicide compositions as biologically active agent, especially for control of phytopathogenic fungi in crop protection and in the protection of industrial materials and as plant growth regulators. The structures of the claimed compounds further show that they are not spiro heterocyclic compounds according to Applicant’s claims. PNG media_image4.png 503 517 media_image4.png Greyscale Gortz does disclose the addition of organic acids. However, as can be seen from the this disclosure, it pertains to a laundry list of possible ingredients, for which there is no motivation to specifically select organic acid in order to achieve improved stability with a reasonable expectation of success. “The compound combination and the composition of the invention may be combined with one or more suitable nutrient(s) and/or fertilizer(s), such as organic acids (e.g., acetic acid, citric acid, lactic acid, malic acid, taurine, etc.), macrominerals (e.g., phosphorous, calcium, magnesium, potassium, sodium, iron, etc.), trace minerals (e.g., boron, cobalt, chloride, chromium, copper, fluoride, iodine, iron, manganese, molybdenum, selenium, zinc, etc.), vitamins, (e.g., vitamin A, vitamin B complex (i.e., vitamin Bi, vitamin B2 , vitamin B3 , vitamin B5 , vitamin B6 , vitamin B7 , vitamin B8 , vitamin B9 , vitamin BI2 , choline) vitamin C, vitamin D, vitamin E, vitamin K.), and/or carotenoids (a-carotene, P-carotene, cryptoxanthin, lutein, lycopene, zeaxanthin, etc.), and combinations thereof. In an aspect, the compound combination and the composition according to the invention may be combined with macro- and micronutrients of plants or microbes, including phosphorous, boron, chlorine, copper, iron, manganese, molybdenum and/or zinc. According to some embodiments, the compound combination and the composition according to the invention may be combined with one or more beneficial micronutrients. Non-limiting examples of micronutrients for use in compositions described herein may include vitamins, (e.g., vitamin A, vitamin B complex (i.e., vitamin Bl, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B8, vitamin B9, vitamin Bl 2, choline) vitamin C, vitamin D, vitamin E, vitamin K, carotenoids (a-carotene, -carotene, cryptoxanthin, lutein, lycopene, zeaxanthin, etc.), macrominerals (e.g., phosphorous, calcium, magnesium, potassium, sodium, iron, etc.), trace minerals (e.g., boron, cobalt, chloride, chromium, copper, fluoride, iodine, iron, manganese, molybdenum, selenium, zinc, etc.), organic acids (e.g., acetic acid, citric acid, lactic acid, malic acid, taurine, etc.), and combinations thereof (BAYFOLAN secure, BAYFOLAN complete, BAYFOLAN energy, BAYFOLAN power, Aglukon GmbH, Germany). In a particular aspect, compositions may comprise phosphorous, boron, chlorine, copper, iron, manganese, molybdenum, and/or zinc, and combinations thereof. For compositions comprising phosphorous, it is envisioned that any suitable source of phosphorous may be used. For example, phosphorus may be derived from a rock phosphate source, such as monoammonium phosphate, diammonium phosphate, monocalcium phosphate, super phosphate, triple super phosphate, and/or ammonium polyphosphate, an organic phosphorous source, or a phosphorous source capable of solubilization by one or more microorganisms (e.g., Penicillium bilaiae).” (p. 64, l.20 -p. 65, l. 10). Any inquiry concerning this communication or earlier communications from the examiner should be directed to SVETLANA M IVANOVA whose telephone number is (571)270-3277. The examiner can normally be reached 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney L. Klinkel can be reached at (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SVETLANA M IVANOVA/ Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

May 26, 2023
Application Filed
Apr 03, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594248
STRESS MANAGEMENT IN HUMAN SUBJECTS IN NEED THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12595227
COMPOSITIONS AND METHODS FOR TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS
2y 5m to grant Granted Apr 07, 2026
Patent 12583850
SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12568970
IMPROVED STABILITY INSECTICIDAL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
2y 5m to grant Granted Mar 10, 2026
Patent 12558336
METABOLIC RESCUE OF RETINAL DEGENERATION
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
99%
With Interview (+51.3%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 828 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month